Numeric Investors LLC purchased a new position in Intercept Pharmaceuticals Inc (NASDAQ:ICPT) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 2,326 shares of the biopharmaceutical company’s stock, valued at approximately $253,000.
A number of other hedge funds and other institutional investors have also made changes to their positions in ICPT. KBC Group NV raised its stake in shares of Intercept Pharmaceuticals by 660.2% in the third quarter. KBC Group NV now owns 897 shares of the biopharmaceutical company’s stock valued at $147,000 after buying an additional 779 shares during the period. Opus Point Partners Management LLC purchased a new stake in shares of Intercept Pharmaceuticals during the third quarter valued at $215,000. Pacer Advisors Inc. raised its stake in shares of Intercept Pharmaceuticals by 9.5% in the third quarter. Pacer Advisors Inc. now owns 1,384 shares of the biopharmaceutical company’s stock valued at $228,000 after buying an additional 120 shares during the period. Marco Investment Management LLC purchased a new stake in shares of Intercept Pharmaceuticals during the third quarter valued at $247,000. Finally, Ladenburg Thalmann Financial Services Inc. raised its stake in shares of Intercept Pharmaceuticals by 39.6% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,630 shares of the biopharmaceutical company’s stock valued at $178,000 after buying an additional 462 shares during the period. Institutional investors own 82.28% of the company’s stock.
Shares of Intercept Pharmaceuticals Inc (NASDAQ:ICPT) traded up 1.49% on Thursday, reaching $107.19. The company’s stock had a trading volume of 438,279 shares. Intercept Pharmaceuticals Inc has a 52-week low of $96.63 and a 52-week high of $177.93. The company has a 50 day moving average price of $117.12 and a 200 day moving average price of $117.11. The company’s market cap is $2.66 billion.
Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings results on Thursday, February 23rd. The biopharmaceutical company reported ($4.84) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($3.74) by $1.10. Intercept Pharmaceuticals had a negative return on equity of 66.97% and a negative net margin of 3,287.95%. The company had revenue of $13 million for the quarter, compared to analysts’ expectations of $8.96 million. During the same quarter in the previous year, the business earned ($3.62) EPS. The company’s revenue for the quarter was up 2966.7% on a year-over-year basis. On average, analysts anticipate that Intercept Pharmaceuticals Inc will post ($16.28) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Numeric Investors LLC Takes Position in Intercept Pharmaceuticals Inc (ICPT)” was first reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this article on another site, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The correct version of this article can be viewed at https://www.chaffeybreeze.com/2017/04/20/numeric-investors-llc-invests-253000-in-intercept-pharmaceuticals-inc-icpt-updated-updated.html.
Several analysts have recently weighed in on the company. Oppenheimer Holdings Inc. set a $200.00 price objective on Intercept Pharmaceuticals and gave the company a “buy” rating in a report on Saturday, February 11th. Cowen and Company restated an “outperform” rating and issued a $225.00 price objective on shares of Intercept Pharmaceuticals in a report on Friday, February 10th. Robert W. Baird restated a “positive” rating on shares of Intercept Pharmaceuticals in a report on Friday, February 10th. Wedbush reaffirmed an “outperform” rating and set a $224.00 target price on shares of Intercept Pharmaceuticals in a research report on Wednesday, February 8th. Finally, FBR & Co reaffirmed a “market perform” rating and set a $200.00 target price on shares of Intercept Pharmaceuticals in a research report on Thursday, February 16th. Three equities research analysts have rated the stock with a sell rating, five have given a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $187.65.
In related news, CMO David Shapiro sold 346 shares of the firm’s stock in a transaction that occurred on Monday, April 3rd. The shares were sold at an average price of $115.00, for a total value of $39,790.00. Following the completion of the transaction, the chief marketing officer now directly owns 46,023 shares of the company’s stock, valued at approximately $5,292,645. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Lisa Bright sold 389 shares of the firm’s stock in a transaction that occurred on Monday, April 3rd. The stock was sold at an average price of $115.00, for a total transaction of $44,735.00. Following the completion of the transaction, the insider now directly owns 22,925 shares of the company’s stock, valued at $2,636,375. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,682 shares of company stock valued at $190,137. 9.20% of the stock is currently owned by company insiders.
About Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.